Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss biopharma company will also make additional payments to the US firm based on regulatory and commercial milestones. Silicon Therapeutics is said to have developed a computational physics platform. The platform […]
PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of small molecule drugs by using a platform technology based on generative chemistry. The company’s machine learning technology can fast track the drug discovery process by designing novel molecular structures that […]
InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the clinical stage company was led by Hillhouse Capital affiliate GL Ventures. Other new investors are Qiming Venture Partners, Janchor, Matrix Partner China, AIHC Capital, Dyee Capital, and E Fund Capital […]
Antoxerene, a pharmaceutical company dedicated to developing senolytic drugs, has partnered with investment firm Juvenescence to form a joint venture named FoxBio. This new entity will focus on advancing small molecule drugs aimed at combating diseases associated with aging. FoxBio’s mission is to develop a series of small molecules from Antoxerene that specifically target senescent […]